PHAXIAM Therapeutics (PHXM) Competitors $3.10 0.00 (0.00%) As of 08/22/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock PHXM vs. XCUR, EGRX, RENB, EQ, CALC, HYPD, AADI, LVTX, SNTI, and KLTOShould you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Exicure (XCUR), Eagle Pharmaceuticals (EGRX), Renovaro (RENB), Equillium (EQ), CalciMedica (CALC), Hyperion DeFi (HYPD), Aadi Bioscience (AADI), LAVA Therapeutics (LVTX), Senti Biosciences (SNTI), and Klotho Neurosciences (KLTO). These companies are all part of the "pharmaceutical products" industry. PHAXIAM Therapeutics vs. Its Competitors Exicure Eagle Pharmaceuticals Renovaro Equillium CalciMedica Hyperion DeFi Aadi Bioscience LAVA Therapeutics Senti Biosciences Klotho Neurosciences Exicure (NASDAQ:XCUR) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Does the media prefer XCUR or PHXM? In the previous week, Exicure had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Exicure and 0 mentions for PHAXIAM Therapeutics. Exicure's average media sentiment score of 0.98 beat PHAXIAM Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the media. Company Overall Sentiment Exicure Positive PHAXIAM Therapeutics Neutral Which has higher valuation & earnings, XCUR or PHXM? PHAXIAM Therapeutics has lower revenue, but higher earnings than Exicure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K76.98-$9.70M-$3.88-1.57PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A Which has more risk and volatility, XCUR or PHXM? Exicure has a beta of 3.67, suggesting that its stock price is 267% more volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Do institutionals & insiders believe in XCUR or PHXM? 42.8% of Exicure shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 3.9% of Exicure shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is XCUR or PHXM more profitable? PHAXIAM Therapeutics' return on equity of 0.00% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -192.16% -84.30% PHAXIAM Therapeutics N/A N/A N/A SummaryExicure beats PHAXIAM Therapeutics on 6 of the 9 factors compared between the two stocks. Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHXM vs. The Competition Export to ExcelMetricPHAXIAM TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.58M$137.17M$5.81B$9.76BDividend YieldN/A3.74%4.39%4.06%P/E RatioN/A3.8731.3626.05Price / SalesN/A4,053.60387.8788.42Price / CashN/A13.1938.0259.36Price / Book0.3946.309.536.60Net Income-$240K-$90.99M$3.26B$265.65M7 Day PerformanceN/A0.64%2.14%2.00%1 Month PerformanceN/A2.73%3.22%0.46%1 Year PerformanceN/A203.46%30.18%18.88% PHAXIAM Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049XCURExicure1.8824 of 5 stars$6.65-2.9%N/A+1,384.3%$42.03M$500K-1.7150Positive NewsGap UpEGRXEagle Pharmaceuticals1.7477 of 5 stars$3.20flatN/A-30.0%$41.56M$257.55M0.00100RENBRenovaroN/A$0.24+0.5%N/A-65.1%$41.15MN/A-0.3120EQEquillium0.9299 of 5 stars$1.14+16.3%$3.00+163.2%+74.4%$40.72M$41.10M-2.9240Gap DownCALCCalciMedica3.4498 of 5 stars$2.91+11.5%$16.00+449.8%-32.4%$40.65MN/A-1.8230HYPDHyperion DeFi0.3635 of 5 stars$7.20+7.6%$2.00-72.2%-86.8%$40.32M$60K-0.1240Gap DownAADIAadi Bioscience0.4419 of 5 stars$1.62-5.3%$1.67+2.9%+10.1%$40.01M$25.07M-0.7140LVTXLAVA Therapeutics1.5174 of 5 stars$1.52-1.3%$2.69+76.6%-19.0%$39.99M$11.98M-1.4560Short Interest ↓SNTISenti Biosciences2.5743 of 5 stars$1.52-0.7%$8.50+459.2%-43.1%$39.76M$2.56M-0.174KLTOKlotho NeurosciencesN/A$0.86+10.4%N/AN/A$39.61MN/A-2.39N/AEarnings ReportGap Up Related Companies and Tools Related Companies Exicure Competitors Eagle Pharmaceuticals Competitors Renovaro Competitors Equillium Competitors CalciMedica Competitors Hyperion DeFi Competitors Aadi Bioscience Competitors LAVA Therapeutics Competitors Senti Biosciences Competitors Klotho Neurosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHXM) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access